Skip to main content
Psyence Group Inc. logo

Psyence Group Inc. — Investor Relations & Filings

Ticker · PSYG ISIN · CA74449Q2053 LEI · 549300RPEOIVSD0MJC07 CSE Manufacturing
Open in API
Filings indexed 387 across all filing types
Latest filing 2022-06-02 Capital/Financing Update
Country CA Canada
Listing CSE PSYG

About Psyence Group Inc.

https://psyence.com/

Psyence Group Inc. is a science-led life science biotechnology company focused on the research, cultivation, and production of natural psychedelics and nature-based compounds. The company develops innovative, safe, and effective solutions for mental health. Its core clinical division, Psyence Therapeutics (now part of Psyence Biomedical Ltd.), pioneers the use of natural psilocybin formulations and treatment protocols, primarily targeting anxiety and depression within the context of palliative care. Supporting this effort, the company operates one of the world's first federally licensed, ISO22000 certified psilocybin cultivation and production facilities. Furthermore, Psyence Function markets a range of non-psychoactive functional mushroom wellness products utilizing adaptogens.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Capital/Financing Update Classification · 95% confidence The document is a corporate update from Psyence Group Inc. It provides detailed information about recent partnerships, appointments, facility upgrades, product launches, private placement financing, and strategic initiatives including capital market exploration and potential dual listing. The content focuses on business developments, operational progress, and financial activities such as a private placement closing. There are no financial statements, quarterly or annual results, nor is this a transcript of a call or a regulatory filing of voting results or director dealings. The document is not a formal report like an Annual Report (10-K) or Interim Report (IR), nor is it a presentation or proxy solicitation. It is a comprehensive corporate update with financial and strategic information, fitting best under Capital/Financing Update (CAP) due to the emphasis on private placement and capital market initiatives. The document length and detail confirm it is not a brief announcement or a report publication notice.
2022-06-02 English
News release - English.pdf
Regulatory Filings
2022-05-31 English
Other securityholders documents - English.pdf
Capital/Financing Update Classification · 95% confidence The document is a detailed pricing supplement for a structured financial product issued by the Canadian Imperial Bank of Commerce (CIBC). It includes terms of the offering, pricing, commission, product description, index reference, and payout structure. The document is a supplement to a base prospectus and is related to a capital raising or securities issuance. It is not a financial report, earnings release, or management discussion. It is not a regulatory filing or announcement of a report but a detailed offering document related to capital markets activity. Therefore, it fits best under the category of Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities.
2022-05-19 English
Other securityholders documents - English.pdf
Governance Information Classification · 95% confidence The document is a detailed set of corporate by-laws for a corporation named ELI - ECO LOGIC INC. It covers sections on interpretation, business of the corporation, borrowing and security, directors, committees, officers, shares, dividends, meetings of shareholders, notices, and effective date. The content is focused on governance structure, rules for directors, meetings, and corporate operations rather than financial results, audit opinions, or shareholder meeting materials. There is no indication of financial statements, earnings data, voting results, or legal proceedings. The document is not a report or announcement of a report but a governance document outlining internal rules and procedures. Therefore, the most appropriate classification is Governance Information (CGR).
2022-05-19 English
News release - English.pdf
Capital/Financing Update Classification · 95% confidence The document is a press release announcing an exclusive licensing agreement between Psyence Group Inc and Filament Health Corp. It discusses the terms of the agreement, the companies' expertise, and future clinical trials. There is no financial data, regulatory filing, or detailed report content. The document is a corporate announcement about a partnership and licensing deal, not a financial report, regulatory filing, or management discussion. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. The content is best classified as a general corporate announcement about a licensing agreement, which aligns with Capital/Financing Update (CAP) as it relates to licensing and partnership agreements impacting company assets and operations.
2022-04-19 English
52-109FV2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings Classification · 95% confidence The document is a certification by the CEO of Psyence Group Inc. regarding the interim financial report and interim MD&A for the period ended December 31, 2021. It is a Form 52-109FV2 Certification of Interim Filings for a Venture Issuer. The text primarily contains the CEO's attestation about the accuracy and fair presentation of the interim filings, without including the actual financial data or detailed financial statements. The document is relatively short (3068 characters) and focuses on certification rather than presenting the interim report itself. According to the Certification Rule, such officer certifications should be classified as Regulatory Filings (RNS) rather than as the interim report (IR).
2022-02-25 English

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.